Show simple item record

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

dc.contributor.authorLIEW, S. H. Melissa
dc.contributor.authorTugal-Tutkun, Ilknur
dc.contributor.authorZIERHUT, Manfred
dc.contributor.authorBEZLYAK, Vladimir
dc.contributor.authorAndroudi, Sofia
dc.contributor.authorDick, Andrew D.
dc.contributor.authorFoster, Stephen
dc.date.accessioned2021-03-03T09:06:37Z
dc.date.available2021-03-03T09:06:37Z
dc.date.issued2013
dc.identifier.citationDick A. D. , Tugal-Tutkun I., Foster S., ZIERHUT M., LIEW S. H. M. , BEZLYAK V., Androudi S., "Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials", OPHTHALMOLOGY, cilt.120, sa.4, ss.777-787, 2013
dc.identifier.issn0161-6420
dc.identifier.otherav_1b3e00a2-06fe-4e0f-961f-8b4b9dbbb29d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/23592
dc.identifier.urihttps://doi.org/10.1016/j.ophtha.2012.09.040
dc.description.abstractPurpose: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.
dc.language.isoeng
dc.subjectGöz Hastalıkları ve Cerrahisi
dc.subjectCerrahi Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectOFTALMOLOJİ
dc.titleSecukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
dc.typeMakale
dc.relation.journalOPHTHALMOLOGY
dc.contributor.departmentUniversity Of Bristol , ,
dc.identifier.volume120
dc.identifier.issue4
dc.identifier.startpage777
dc.identifier.endpage787
dc.contributor.firstauthorID25075


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record